TG Therapeutics Statistics
Total Valuation
TG Therapeutics has a market cap or net worth of $8.87 billion. The enterprise value is $9.12 billion.
| Market Cap | 8.87B |
| Enterprise Value | 9.12B |
Important Dates
The last earnings date was Monday, November 9, 2026, before market open.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TG Therapeutics has 140.10 million shares outstanding. The number of shares has decreased by -2.16% in one year.
| Current Share Class | 140.10M |
| Shares Outstanding | 140.10M |
| Shares Change (YoY) | -2.16% |
| Shares Change (QoQ) | -0.86% |
| Owned by Insiders (%) | 4.68% |
| Owned by Institutions (%) | 88.18% |
| Float | 133.50M |
Valuation Ratios
The trailing PE ratio is 95.92 and the forward PE ratio is 23.44. TG Therapeutics's PEG ratio is 1.53.
| PE Ratio | 95.92 |
| Forward PE | 23.44 |
| PS Ratio | 9.88 |
| Forward PS | 6.97 |
| PB Ratio | 15.51 |
| P/TBV Ratio | 15.51 |
| P/FCF Ratio | 103.71 |
| P/OCF Ratio | 102.88 |
| PEG Ratio | 1.53 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 47.26, with an EV/FCF ratio of 106.63.
| EV / Earnings | 86.02 |
| EV / Sales | 10.16 |
| EV / EBITDA | 47.26 |
| EV / EBIT | 47.31 |
| EV / FCF | 106.63 |
Financial Position
The company has a current ratio of 4.50, with a Debt / Equity ratio of 1.32.
| Current Ratio | 4.50 |
| Quick Ratio | 3.54 |
| Debt / Equity | 1.32 |
| Debt / EBITDA | 3.87 |
| Debt / FCF | 8.82 |
| Interest Coverage | 4.14 |
Financial Efficiency
Return on equity (ROE) is 17.99% and return on invested capital (ROIC) is 17.63%.
| Return on Equity (ROE) | 17.99% |
| Return on Assets (ROA) | 8.10% |
| Return on Invested Capital (ROIC) | 17.63% |
| Return on Capital Employed (ROCE) | 14.48% |
| Weighted Average Cost of Capital (WACC) | 13.43% |
| Revenue Per Employee | $2.25M |
| Profits Per Employee | $265,810 |
| Employee Count | 399 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 0.91 |
Taxes
In the past 12 months, TG Therapeutics has paid $43.49 million in taxes.
| Income Tax | 43.49M |
| Effective Tax Rate | 29.08% |
Stock Price Statistics
The stock price has increased by +108.84% in the last 52 weeks. The beta is 1.81, so TG Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 1.81 |
| 52-Week Price Change | +108.84% |
| 50-Day Moving Average | 57.58 |
| 200-Day Moving Average | 46.25 |
| Relative Strength Index (RSI) | 57.18 |
| Average Volume (20 Days) | 2,197,659 |
Short Selling Information
The latest short interest is 28.77 million, so 20.53% of the outstanding shares have been sold short.
| Short Interest | 28.77M |
| Short Previous Month | 29.59M |
| Short % of Shares Out | 20.53% |
| Short % of Float | 21.55% |
| Short Ratio (days to cover) | 18.16 |
Income Statement
In the last 12 months, TG Therapeutics had revenue of $897.76 million and earned $106.06 million in profits. Earnings per share was $0.66.
| Revenue | 897.76M |
| Gross Profit | 742.84M |
| Operating Income | 192.86M |
| Pretax Income | 149.55M |
| Net Income | 106.06M |
| EBITDA | 193.04M |
| EBIT | 192.86M |
| Earnings Per Share (EPS) | $0.66 |
Balance Sheet
The company has $504.67 million in cash and $754.37 million in debt, with a net cash position of -$249.70 million or -$1.78 per share.
| Cash & Cash Equivalents | 504.67M |
| Total Debt | 754.37M |
| Net Cash | -249.70M |
| Net Cash Per Share | -$1.78 |
| Equity (Book Value) | 572.13M |
| Book Value Per Share | 4.08 |
| Working Capital | 910.92M |
Cash Flow
In the last 12 months, operating cash flow was $86.26 million and capital expenditures -$693,000, giving a free cash flow of $85.56 million.
| Operating Cash Flow | 86.26M |
| Capital Expenditures | -693,000 |
| Depreciation & Amortization | 179,000 |
| Net Borrowing | 492.66M |
| Free Cash Flow | 85.56M |
| FCF Per Share | $0.61 |
Margins
Gross margin is 82.74%, with operating and profit margins of 21.48% and 11.81%.
| Gross Margin | 82.74% |
| Operating Margin | 21.48% |
| Pretax Margin | 16.66% |
| Profit Margin | 11.81% |
| EBITDA Margin | 21.50% |
| EBIT Margin | 21.48% |
| FCF Margin | 9.53% |
Dividends & Yields
TG Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 2.16% |
| Shareholder Yield | 2.16% |
| Earnings Yield | 1.04% |
| FCF Yield | 0.96% |
Analyst Forecast
The average price target for TG Therapeutics is $69.43, which is 9.62% higher than the current price. The consensus rating is "Buy".
| Price Target | $69.43 |
| Price Target Difference | 9.62% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 39.31% |
| EPS Growth Forecast (3Y) | 9.93% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
The last stock split was on April 30, 2012. It was a reverse split with a ratio of 1:56.25.
| Last Split Date | Apr 30, 2012 |
| Split Type | Reverse |
| Split Ratio | 1:56.25 |
Scores
TG Therapeutics has an Altman Z-Score of 4.12 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.12 |
| Piotroski F-Score | 5 |